Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Aug;24(8):1339-41.
doi: 10.1038/mt.2016.165.

Like Angler Fish, CAARs Lure Their Prey

Anne Galy  1
Affiliations
Comment

Like Angler Fish, CAARs Lure Their Prey

Anne Galy. Mol Ther. 2016 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
How desmoglein 3–chimeric autoantigen receptor (Dsg3-CAAR) T cells lure and specifically eliminate autoreactive anti-Dsg3 B cells responsible for skin blistering in pemphigus vulgaris (PV) while sparing normal B cells. PV is a severe autoimmune disease caused by pathogenic autoreactive B cells expressing B-cell receptors (BCR) with immunoglobulins (Ig) specific for desmoglein-3 (Dsg3). These autoantibodies perturb the adhesion of keratinocytes and cause skin blistering. Dsg3-autoreactive B cells can be lured to their own demise when they engage their BCR onto genetically engineered T cells expressing a Dsg3-CAAR (Dsg3-CAAR T cells). The BCR recognizes the ectodomain of the CAAR, exposing four cadherin domains of Dsg3 as epitopes. This extracellular portion of the CAAR is linked to a CD137/CD3zeta chain that permits intracellular signaling and cytolytic activation of the T cell. A synapse forms between the Dsg3-CAAR T cell and Dsg3-specific B cells, cytokines are produced, and B-cell lysis occurs. By contrast, B cells with other BCRs (green) are not recognized and are not killed by Dsg3-CAAR T cells.
See this image and copyright information in PMC

Comment on

References

    1. Tasian, SK and Gardner, RA (2015). CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 6: 228–241. - PMC - PubMed
    1. Ruella, M and June, CH (2016). Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep; e-pub ahead of print 30 July 2016. - PubMed
    1. Ellebrecht, CT, Bhoj, V, Nace, A, Choi, EJ, Mao, X, Cho, MJ et al. (2016). Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353: 179–184. - PMC - PubMed
    1. Jensen, MC and Riddell, SR (2015). Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33: 9–15. - PMC - PubMed
    1. Sette, A, Paul, S, Vaughan, K and Peters, B (2015). The use of the immune epitope database to study autoimmune epitope data related to alopecia areata. J Investig Dermatol 17: 36–41. - PMC - PubMed

Substances